April 29, 2020 / 12:45 PM / 25 days ago

BRIEF-FDA Submission To Change The Primary Endpoint Into An Industry First And Robust Clinical Measure For Superiority Of CIN Phase 3 Study

April 29 (Reuters) - Beyondspring Inc:

* FDA SUBMISSION TO CHANGE THE PRIMARY ENDPOINT INTO AN INDUSTRY FIRST AND ROBUST CLINICAL MEASURE FOR SUPERIORITY OF CIN PHASE 3 STUDY

* BEYONDSPRING INC - NEW PRIMARY ENDPOINT WILL BE RATE OF PREVENTION OF GRADE 4 NEUTROPENIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below